Evolving Management Strategies for BRAF-Mutant Metastatic Colorectal Cancer

Evolving Management Strategies for BRAF-Mutant Metastatic Colorectal Cancer

Evolving Management Strategies for BRAF-Mutant Metastatic Colorectal Cancer
RestartResume

Here’s how you can treat the up to 15 percent of metastatic colorectal cancer patients with BRAF mutations based on the latest trends and research.

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.

    This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Employ molecular testing for BRAF V600E mutations for all mCRC patients to identify those individuals who would benefit from a targeted therapeutic regimen.
    2. Apply recent data and appropriate targeted treatment regimens for patients with BRAF V600E–mutated mCRC.
    3. Identify the need and apply appropriate management strategies for treatment-related adverse events in patients with BRAF-mutated mCRC.
  • Target Audience

    This educational activity is for medical oncologists, pathologists/lab professionals, oncology nurses, nurse practitioners, pharmacists, physician assistants, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with BRAF-mutant CRC.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Scott Kopetz, MD, PhD, reported a financial interest/relationship or affiliation in the form of Stocks and other ownership interests: MolecularMatch, Navire, Lutris, and Iylon. Consultant: Genentech, Inc; EMD Serono, Inc; Merck & Co, Inc; Holy Stone; Novartis Pharmaceuticals Corp; Lilly USA; Boehringer Ingelheim; Boston Biomedical; AstraZeneca Pharmaceuticals/MedImmune; Bayer HeatlhCare, Inc; Pierre Fabre; EMD Serono, Inc; Redx Pharma; Ipsen Pharmaceuticals; Daiichi-Sankyo, Inc; Natera, Inc; HalioDx, Lutris; Jacobio; Pfizer, Inc; Repare Therapeutics; Inivata; GlaxoSmithKline; Jazz Pharmaceuticals; Iylon; Xilis; AbbVie; Amal Therapeutics; Gilead Sciences; Mirati Therapeutics; Flame Biosciences; Servier; Carina Biotechnology; Bicara Therapeutics; Endeavor BioMedicines; and Numab Pharma. Research funding to MD Anderson Cancer Center: sanofi; Biocartis; Guardant Health, Inc; Array BioPharma; Genentech/Roche; EMD Serono, Inc; MedImmune; Novartis Pharmaceuticals Corp; Amgen, Inc; Lilly USA; and Daiichi-Sankyo, Inc.

    Rona Yaeger, MD, reported a financial interest/relationship or affiliation in the form of Advisor: Array BioPharma/Pfizer, Natera, and Mirati Therapeutics. Research grant: Pfizer, Inc and Boehringer Ingelheim.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Jeffrey Stein; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING  EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive  1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/2/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-21-097-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0  contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

    Are you requesting ASCP CMLE Credit? If yes, an ASCP CMLE certificate will be emailed to you.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • Terms of Use

    Disclosure of Unlabeled Use     
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:            
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free